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IMPORTANCE Perimenopause is accompanied by an increased risk of new and recurrent
depression. The coincidence of declining ovarian function with the onset of depression led to
the inference that “withdrawal” from physiologic estradiol levels underpinned depression in
perimenopause. To our knowledge, this is the first controlled systematic study to directly test
the estrogen withdrawal theory of perimenopausal depression (PMD).
OBJECTIVE To examine the role of estradiol withdrawal in PMD.
DESIGN, SETTING, AND PARTICIPANTS Initial open-label treatment with estradiol followed by
randomized, double-blind, placebo-controlled, parallel-design evaluation of continued
estradiol treatment was evaluated at an outpatient research facility at the National Institutes
of Health Clinical Center. An intent-to-treat analysis was performed between October 2003
and July 2012. Participants included asymptomatic postmenopausal women with past PMD
responsive to hormone therapy (n = 26) and asymptomatic postmenopausal women with no
history of depression (n = 30) matched for age, body mass index, and reproductive status
who served as controls. Data were analyzed between November 2012 and October 2013 by
repeated-measures analysis of variance.
INTERVENTIONS After 3 weeks of open-label administration of transdermal estradiol (100
μg/d), participants were randomized to a parallel design to receive either estradiol (100 μg/d;
27 participants) or matched placebo skin patches (29 participants) for 3 additional weeks
under double-blind conditions.
MAIN OUTCOMES AND MEASURES Center for Epidemiologic Studies–Depression Scale and
17-item Hamilton Depression Rating Scale (completed by raters blind to diagnosis and
randomization status), self-administered visual analog symptom ratings, and blood hormone
levels obtained at weekly clinic visits.
RESULTS None of the women reported depressive symptoms during open-label use of
estradiol. Women with past PMD who were crossed over from estradiol to placebo experienced
a significant increase in depression symptom severity demonstrated using the Center for
Epidemiologic Studies–Depression Scale and 17-item Hamilton Depression Rating Scale, with
mean (SD) scores increasing from estradiol (ie, 2.4 [2.0] and 3.0 [2.5]) to placebo (8.8 [4.9] and
6.6 [4.5], respectively [P = .0004 for both]). Women with past PMD who continued estradiol
therapy and all women in the control group remained asymptomatic. Women in both groups
had similar hot-flush severity and plasma estradiol levels during use of placebo.
CONCLUSIONS AND RELEVANCE In women with past PMD that was previously responsive to
hormone therapy, the recurrence of depressive symptoms during blinded hormone
withdrawal suggests that normal changes in ovarian estradiol secretion can trigger an
abnormal behavioral state in these susceptible women. Women with a history of PMD should
be alert to the risk of recurrent depression when discontinuing hormone therapy.
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D epression risk increases in perimenopause, and de-pression is cited1-3 as a primary reason for resumingmenopausal hormone therapy (HT). Community-
based epidemiologic studies4-8 have documented a 1.5- to 3-fold
greater risk of first onset of depression and recurrent depres-
sion in women in perimenopause compared with those who
are premenopausal or several years postmenopausal. Obser-
vational studies9-11 have reported the emergence of depres-
sive symptoms after the discontinuation of HT in 5% to 10%
of women.
The role of estradiol—either declining levels or low lev-
els—in the precipitation of perimenopausal depression (PMD)
is unknown, largely owing to the associational and indirect na-
ture of the evidence linking ovarian function and depression.
Correlative studies7,12-15 with plasma follicle-stimulating hor-
mone (FSH) or response to HT provided indirect evidence of
the association between changes in reproductive hormones and
mood disturbances. However, even prospective epidemio-
logic studies cannot test the estradiol withdrawal hypothesis
since perimenopausal changes in the secretion of several hor-
monal and metabolic factors could confound the effects of es-
tradiol withdrawal. In other studies16,17 of the role of ovarian
steroids in affective disturbance, changes in ovarian steroids
(in the context of otherwise normal levels) have been shown
to directly trigger depression, but only in a subset of women
with histories of mood disorders linked to reproductive func-
tion. In the present study, we directly examined the hypoth-
esis that declining ovarian function (estradiol withdrawal) un-
derpins depression occurring in perimenopause. We further
sought to examine whether the response to estradiol with-




Between October 2003 and July 2012, women were self-referred
in response to newspaper advertisements or were referred by
a physician. All women were aged 45 to 65 years, postmeno-
pausal, and in good health; none had clinically significant mood
symptoms. We recruited 2 groups of women. The first group
comprised women with past perimenopausal depression who
reported a history of major or minor depression (confirmed by
the Structured Clinical Interview for DSM-IV18) at midlife in as-
sociationwithmenstrualcycleirregularity(ie,skippedmenstrual
periods or prolonged periods of amenorrhea), with remission
(also confirmed by the Structured Clinical Interview retrospec-
tively) of this depression after HT (past PMD). In addition, many
women reported the experience of distressing vasomotor symp-
toms and/or vaginal dryness proximate to the episode of de-
pression. The second group included matched asymptomatic
women who were either currently receiving HT or had previ-
ously received HT and who had no past depression (controls)
(eMethods in Supplement 1). The trial protocol was approved
by the National Institute of Mental Health Intramural Research
Board and appears in Supplement 2, and all women provided
oral and written informed consent. All participants received fi-
nancial compensation according to the guidelines of the Na-
tional Institutes of Health Healthy Volunteer Office.
Study Design
During a 3-week baseline phase, all women received open-
label transdermal estradiol (Vivelle-Dot) therapy (100 μg/d) and
completed symptom ratings to confirm the absence of mood
symptoms before entry into the double-blind study (Figure 1).
After determination that mood symptoms remained absent
during open-label use of estradiol, women were randomized
to a parallel design in which they received either estradiol (at
the same dose given during the open-label period) or matched
placebo skin patches for 3 additional weeks. At the end of the
trial, all women received 1 week of oral medroxyprogester-
one acetate (5 mg/d) to induce progestin-withdrawal men-
strual bleeding. All women attended weekly outpatient visits
in which outcome measures were obtained, adverse effects
were monitored, and blood samples were drawn.
Assessment of Symptoms
Depressive symptoms were monitored with rating scales
completed during weekly clinic visits, including the self-
rated Center for Epidemiologic Studies–Depression Scale
(CES-D)19 and the 17-item Hamilton Depression Rating Scale
(HDRS)20 (completed by blinded raters). As secondary mea-
sures, women completed the Beck Depression Inventory21
and a visual analog scale measuring the severity of 11 mood
and behavioral symptoms. Finally, to monitor the presence
and severity of vasomotor symptoms, women completed a
daily rating form.22
Figure 1. CONSORT Diagram
121 Women assessed for eligibility
65 Excluded
40 Did not meet inclusion criteria
21 Declined to participate
4 Other reasons
56 Randomized
12 With past PMD
15 Controls
27 Included in the primary analysis
14 With past PMD
15 Controls
29 Included in the primary analysis
0 Lost to follow-up
0 Discontinued intervention
0 Lost to follow-up
0 Discontinued intervention
27 Randomized to estradiol




0 Did not receive intervention
as randomized
29 Randomized to placebo




0 Did not receive intervention
as randomized
All women were postmenopausal; therefore, endogenous estradiol production
did not contribute to the changes in reproductive hormones that were observed.
Twenty-three women with past perimenopausal depression (PMD) and 16
control women were receiving hormone therapy before starting the study.
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Statistical Analysis
An intent-to-treat analysis was performed between Novem-
ber 2012 and October 2013. We first tested for significant dif-
ferences in mood symptoms developing during the double-
blind conditions compared with the open-label (baseline)
conditions in each of the 4 groups (ie, women with and
without past PMD randomized to double-blind administra-
tion of estradiol or placebo). Second, we compared symp-
tom ratings during double-blind treatment conditions
across all 4 randomization groups (ie, women with and
those without past PMD who were randomized to either
estradiol or placebo).
We obtained 6 repeated measures on the same woman
during the baseline (3 weekly measures) and double-blind (3
weekly measures) phases. Analyses were done with SAS,
version 9.2 (SAS Institute Inc), repeated-measures analysis
of variance using PROC MIXED (for mixed models). For each
symptom rating and blood hormone level, the predictor
variables of interest—double-blind treatment (placebo or
estradiol) and history of PMD (yes or no)—were modeled as
fixed effects. The covariance pattern across time was struc-
tured as first-order autoregressive. We used the Kenward-
Roger method for computing the degrees of freedom for
tests of fixed effects.
For each of the 16 symptom outcomes, we performed 2
types of analyses to explore the effect of a history of PMD in
the 2 treatment groups. We first compared mood symptom val-
ues during the double-blind conditions vs during the open-
label (baseline) conditions separately in each of the 4 groups
(ie, women with and without past PMD randomized to estra-
diol or placebo). Second, we compared symptom ratings dur-
ing double-blind treatment conditions in 4 ways (ie, women
with vs without past PMD in the estradiol group; similarly for
women in the placebo group). In the first analysis, we deter-
mined whether symptoms changed from baseline (ie, open-
label estradiol, weeks 1-3 of the trial) to the double-blind
treatment phase (ie, weeks 4-6 of the trial) in any of the 4 ran-
domization groups (as described above). For the second analy-
sis, we included the mean of the baseline symptom measure
for each symptom as a covariate (since symptom rating scores
were higher in the women with past PMD compared with con-
trol women despite receiving open-label estradiol) and com-
pared differences in symptom ratings across each of the 4 ran-
domization groups to test for the effects of past PMD and
double-blind treatment. Plasma levels of estradiol, estrone, and
FSH during double-blind treatment also were analyzed across
randomization groups. For all analyses, the value of the esti-
mator (least square means) and associated SE of the estimator
and P values are reported. For each symptom measure, the P
values reported are the Bonferroni value adjusted for mul-
tiple comparisons within that symptom, and 2-sided P < .05 was
considered statistically significant.
Clinical characteristics in women with past PMD and con-
trol women were compared to ensure similarity across groups
and included the following measures: age, body mass index,
menstrual bleeding, weekly mean hot-flush severity scores of
2 or more (minimal severity), and CES-D score. The CES-D cut-
off scores are typically used as a screen to identify clinically
significant depression; a cutoff score of greater than 16 has been
shown4,23,24 to correlate with clinically significant depres-
sion. In addition, a score between 8 and 15 has been used to
define subsyndromal depression.25-27 We used the Fisher ex-
act test for categorical variables and t tests for continuous
variables.
Finally, the possible relationships between the magni-
tude of the change in plasma estradiol and FSH levels and
mood symptoms in women with past PMD in whom estra-
diol therapy was withdrawn were examined using Spearman
correlation coefficients as follows. The difference between
the mean plasma estradiol or FSH levels during open-label
administration of estradiol and those during administration
of placebo were correlated with both the corresponding dif-
ferences in CES-D symptom scores and the maximum CES-D




Sixty women entered the trial: 30 women had past PMD and
30 had no history of depression. Four women with past PMD
were excluded from the trial after the open-label phase: 1
was not adherent to treatment, and 3 experienced distress-
ing life events that affected their participation (Figure 1 and
Table 1).
Women with past PMD and control women did not differ
significantly in the following measures: mean (SD) age, 55.5
(4.4) and 56.3 (3.7) years, respectively; body mass index, 26.1
(4.9) and 26.4 (5.3) (calculated as weight in kilograms
divided by height in meters squared), respectively; and time
since the last menstrual period, 6.7 (3.9) and 5.9 (3.5) years,
respectively (t test, P > .05 for all comparisons). Eighteen of
the 26 women with PMD had a past major depression in peri-
menopause and 8 had a past minor depression in perimeno-
pause (ie, did not meet the full 5 criteria required for major
depression). Four of the 26 women with past PMD reported
additional episodes of major depression that were premeno-
pausal (ie, unrelated to the menopause transition), 3 of
whom were randomized to estradiol and 1 to placebo. One of
these 4 women with a past major depression reported symp-
toms of premenstrual irritability in the past, but none of
these women reported episodes of prenatal or postpartum
depression.
Symptom Ratings
Comparisons Between Open-Label and Double-blind Conditions
Women with past PMD who were randomized to placebo
experienced a significant increase in depression severity rat-
ings (ie, CES-D, HDRS [P < .001, both comparisons] and Beck
Depression Inventory scores [the last at a trend of P = .05])
as well as in several of the visual analog scale symptom
scores (depression, social isolation, early morning wakening,
and feeling unmotivated) compared with their baseline
estradiol treatment (Table 2, Figure 2). The other 3 groups
remained asymptomatic and did not experience a significant
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change in depression symptom severity during the double-
blind conditions compared with open-label estradiol admin-
istration. Neither of the placebo groups experienced a sig-
nificant increase in the severity of day and nighttime hot
flushes.
Comparisons Across Groups During Double-blind Conditions
While receiving placebo, women with past PMD had signifi-
cantly increased depression scores compared with both the
women with past PMD who were randomized to estradiol
(ie, continuation) and control women who received placebo
(Table 3, Figure 2). This pattern of significant effects of estra-
diol withdrawal on mood in the women with past PMD was
observed in depression severity measures (ie, CES-D [com-
pared with controls receiving placebo, P < .001; compared
with women with past PMD receiving estradiol, P < .001],
HDRS [compared with controls receiving placebo, P < .001;
compared with women with past PMD receiving estradiol,
P = .002], and Beck Depression Inventory [compared with
controls receiving placebo, P = .02; compared with women
with past PMD receiving estradiol, P = .03]) as well as in sev-
eral visual analog scale symptom scores. In addition, there
were no significant differences in any symptom score mea-
sured in women with no past history of depression (control
women) who received double-blind estradiol compared with
control women who received placebo (withdrawal); P values
were nonsignificant for all comparisons. Nor were there sig-
nificant differences in the CES-D, Beck Depression Inven-
tory, HDRS, or any of the visual analog scale symptom scores
between women with a past PMD during double-blind estra-
diol administration compared with the control women. No
significant differences in either daytime or nighttime hot-
flush severity were observed between women with past
PMD and control women who received placebo (P = .23 and
.82, respectively). There also were no significant differences
in hot-flush severity between placebo and estradiol use dur-
ing the double-blind phase in either the women with past
PMD or the control women (Table 3; P values ranged from .18
to .51).
Plasma Hormone Levels
Plasma hormone levels (Table 4) did not differ significantly be-
tween the women with PMD and control women during the
double-blind conditions. Otherwise, plasma hormone levels
showed expected differences, predicted by the study design,
between double-blind administration of estradiol and pla-
cebo in both women with PMD and control women.
Additional Comparisons
During placebo administration, 5 women with past PMD
(36%) and none of the control women had clinically signifi-
cant depression based on self-rating depression scores













Age, mean (SD), y 54.8 (5.2) 56.1 (3.8) 56.0 (3.1) 56.7 (4.3) .45
BMI, mean (SD) 25.3 (4.3) 26.7 (6.5) 25.6 (5.5) 26.1 (3.6) .68
Years since LMP, mean (SD) 5.8 (3.7) 7.1 (4.2) 5.6 (3.1) 6.2 (4.0) .45
Reported PMS, No. (%) 6 (50) 8 (57) 1 (7) 0 NA
Past MDE, No. (%) 3 (25) 1 (7) 0 0 NA
Past PPD (non-SCID), No. (%)b 2 (17) 1 (7) 0 0 NA
STRAW Stage, No. (%)c
Stage +1 6 (50) 5 (36) 8 (53) 6 (4) NA
Stage +2 6 (50) 9 (64) 7 (47) 9 (60) NA
Current smoker, No. (%) 2 (17) 1 (7) 0 0 NA
Pregnancy history, No. (%)
Never pregnant, No. (%) 1 (8) 3 (21) 4 (27) 2 (13) NA
Nulliparity 3 (25) 3 (21) 4 (27) 3 (20) NA
Prestudy symptom scores, mean (SD)
CES-D 7.9 (8.3) 6.1 (6.1) 1.9 (2.8) 1.2 (3.4) NA
HDRS 4.6 (7.1) 4.5 (4.6) 0.3 (0.7) 1.2 (2.4) NA
BDI 3.1 (3.9) 3.4 (5.5) 0.0 (0.0) 0.7 (1.8) NA
Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index
(calculated as weight in kilograms divided by height in meters squared);
CES-D, Center for Epidemiologic Studies–Depression Scale; HDRS, Hamilton
Depression Rating Scale; LMP, last menstrual period; MDE, major depressive
episode; NA, not applicable; PMD, perimenopausal depression;
PMS, premenstrual syndrome; PPD, postpartum depression; SCID, Structured
Clinical Interview for DSM-IV; STRAW, Stages of Reproductive Aging Workshop
Criteria.
a The t test was used to compare age, BMI, and years since LMP between
women with past PMD and control women. Statistical comparisons were not
performed for clinical characteristics that were not relevant to outcomes and
are provided for descriptive purposes only (including prestudy mood ratings).
b Diagnoses of PPD did not meet the SCID criterion requiring onset of
depression to occur within 4 weeks of delivery.
c Stage +1, within 4 years of LMP; stage +2, after 4 years since LMP.28
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Table 2. Comparisons of Symptom Rating Scores During Open-Label and Double-blind Treatment
Measure Past PMD Phase
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
CES-D score Yes OL Estradiol 2.4 (1.0) 2.4 (2.0)
.0004
Placebo 9.1 (1.0) 8.8 (4.9)
Yes OL Estradiol 3.1 (0.5) 3.1 (1.6)
>.99
DB Estradiol 2.8 (0.5) 2.8 (1.5)
No OL Estradiol 0.9 (0.4) 0.9 (1.5)
>.99
Placebo 1.1 (0.4) 1.1 (1.8)
No OL Estradiol 1.4 (0.5) 1.4 (2.2)
.13
DB Estradiol 0.8 (0.5) 0.8 (1.4)
HDRS score Yes OL Estradiol 3.0 (0.9) 3.0 (2.5)
.0004
Placebo 7.0 (0.9) 6.6 (4.5)
Yes OL Estradiol 3.5 (0.7) 3.6 (1.8)
>.99
DB Estradiol 3.1 (0.7) 3.1 (2.6)
No OL Estradiol 0.9 (0.2) 0.9 (0.8)
>.99
Placebo 0.9 (0.2) 0.9 (0.9)
No OL Estradiol 0.8 (0.3) 0.8 (1.1)
>.99
DB Estradiol 0.7 (0.3) 0.7 (1.1)
BDI score Yes OL Estradiol 1.7 (0.8) 1.7 (2.3)
.05
Placebo 4.4 (0.9) 4.3 (3.7)
Yes OL Estradiol 1.7 (0.5) 1.7 (1.8)
.42
DB Estradiol 1.1 (0.5) 1.1 (1.5)
No OL Estradiol 0.2 (0.1) 0.2 (0.3)
.84
Placebo 0.2 (0.1) 0.2 (0.4)
No OL Estradiol 0.2 (0.1) 0.2 (0.4)
.36
DB Estradiol 0.04 (0.1) 0.04 (0.2)
Visual analog scale
Depression Yes OL Estradiol 5.5 (2.3) 5.5 (6.1)
.01
Placebo 14.1 (2.3) 14.0 (10.2)
Yes OL Estradiol 5.3 (1.7) 5.5 (3.5)
>.99
DB Estradiol 6.7 (1.7) 6.8 (7.4)
No OL Estradiol 2.8 (0.4) 2.8 (1.7)
>.99
Placebo 2.6 (0.4) 2.5 (1.8)
No OL Estradiol 3.0 (0.5) 2.9 (2.2)
.45
DB Estradiol 2.4 (0.5) 2.4 (1.1)
Anxiety Yes OL Estradiol 8.6 (3.9) 8.6 (10.4)
.07
Placebo 18.5 (3.9) 18.2 (17.6)
Yes OL Estradiol 11.2 (2.7) 11.5 (9.7)
>.99
DB Estradiol 9.7 (2.6) 9.6 (9.0)
No OL Estradiol 3.0 (0.6) 3.0 (2.3)
>.99
Placebo 2.8 (0.6) 2.9 (2.3)
No OL Estradiol 4.1 (1.8) 4.3 (5.7)
>.99
DB Estradiol 5.6 (1.8) 5.3 (8.4)
Irritability Yes OL Estradiol 10.1 (3.8) 10.1 (10.4)
.11
Placebo 20.4 (3.8) 20.4 (17.5)
Yes OL Estradiol 11.0 (2.3) 11.1 (8.9)
.11
DB Estradiol 7.6 (2.3) 7.7 (7.1)
No OL Estradiol 2.7 (0.5) 2.8 (1.6)
.83
Placebo 2.8 (0.5) 2.8 (2.3)
No OL Estradiol 4.5 (1.2) 4.6 (5.8)
.43
DB Estradiol 2.3 (1.2) 2.3 (1.1)
(continued)
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Table 2. Comparisons of Symptom Rating Scores During Open-Label and Double-blind Treatment (continued)
Measure Past PMD Phase
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
Avoid socializing Yes OL Estradiol 5.8 (2.3) 5.8 (6.3)
.03
Placebo 12.4 (2.3) 12.4 (10.5)
Yes OL Estradiol 6.5 (1.7) 7.0 (8.9)
>.99
DB Estradiol 5.0 (1.7) 4.9 (3.7)
No OL Estradiol 2.3 (0.4) 2.3 (1.5)
>.99
Placebo 2.5 (0.4) 2.4 (1.8)
No OL Estradiol 2.6 (0.3) 2.5 (1.4)
>.99
DB Estradiol 2.5 (0.3) 2.5 (1.0)
Early morning
wakening
Yes OL Estradiol 9.6 (3.3) 9.5 (10.0)
.04
Placebo 15.6 (3.3) 15.8 (14.4)
Yes OL Estradiol 13.9 (2.7) 13.7 (7.1)
>.99
DB Estradiol 13.1 (2.6) 13.5 (9.5)
No OL Estradiol 4.0 (1.0) 4.1 (5.0)
>.99
Placebo 3.3 (1.0) 3.3 (3.2)
No OL Estradiol 3.5 (0.7) 3.3 (1.7)
>.99
DB Estradiol 3.5 (0.7) 3.3 (3.6)
Anhedonia Yes OL Estradiol 5.6 (2.3) 5.6 (5.5)
.07
Placebo 12.4 (2.3) 12.4 (11.3)
Yes OL Estradiol 7.3 (2.2) 8.0 (8.8)
>.99
DB Estradiol 6.1 (2.1) 5.2 (3.7)
No OL Estradiol 2.1 (0.4) 2.1 (1.3)
>.99
Placebo 2.3 (0.4) 2.3 (1.7)
No OL Estradiol 2.4 (0.3) 2.4 (1.2)
>.99
DB Estradiol 2.3 (0.3) 2.4 (1.0)
Decreased energy Yes OL Estradiol 10.9 (3.2) 10.9 (9.3)
.18
Placebo 18.9 (3.2) 18.9 (14.0)
Yes OL Estradiol 12.4 (3.2) 12.7 (14.7)
>.99
DB Estradiol 9.5 (3.1) 9.6 (7.8)
No OL Estradiol 3.1 (0.6) 3.1 (2.2)
>.99
Placebo 2.9 (0.6) 2.9 (2.0)
No OL Estradiol 3.2 (0.5) 3.2 (1.7)
>.99
DB Estradiol 3.0 (0.5) 3.0 (2.0)
Disturbed sleep Yes OL Estradiol 13.5 (3.8) 13.5 (11.3)
.09
Placebo 22.8 (3.9) 22.7 (17.7)
Yes OL Estradiol 21.6 (4.1) 22.2 (14.9)
.20
DB Estradiol 15.5 (4.1) 15.6 (13.2)
No OL Estradiol 4.7 (1.7) 4.8 (7.2)
>.99
Placebo 4.3 (1.7) 4.2 (5.1)
No OL Estradiol 3.6 (0.7) 3.4 (1.9)
>.99
DB Estradiol 3.9 (0.7) 3.8 (4.2)
Unmotivated Yes OL Estradiol 6.6 (2.7) 6.6 (6.5)
.02
Placebo 14.9 (2.7) 14.0 (12.8)
Yes OL Estradiol 5.8 (1.6) 5.6 (4.7)
>.99
DB Estradiol 6.7 (1.6) 7.0 (7.4)
No OL Estradiol 3.3 (0.8) 4.3 (7.8)
>.99
Placebo 3.1 (0.8) 2.7 (1.6)
No OL Estradiol 2.8 (0.4) 3.4 (2.0)
>.99
DB Estradiol 2.6 (0.4) 2.6 (1.1)
(continued)
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(CES-D scores) of 16 or higher. During double-blind estradiol
therapy, no woman had CES-D scores at that level (Fisher
exact test, P < .001). Including women who met our crite-
rion scores for subsyndromal depression (ie, CES-D scores
≥8), depressive symptoms were reported in a total of 11
women (79%) with past PMD during placebo, 1 woman (8%)
with past PMD receiving double-blind estradiol, and 1
woman (7%) from each control group who were randomized
to either placebo or estradiol (Fisher exact test, P < .001 for
all comparisons). No significant differences were observed
between women with past PMD and control women in the
numbers reporting either hot-flush severity of 2 (minimal)
or more or menstrual bleeding during administration of pla-
cebo (Fisher exact text, P > .99 for all comparisons). In the
double-blind phase of the trial, the numbers of participants
with past PMD and control women who reported hot-flush
severity of 2 or more during placebo use did not differ sig-
nificantly from those receiving estradiol (Fisher exact test,
P = .17 and P = .22 for past PMD and control women, respec-
tively). Seven-day mean scores of hot-flush severity of 2
(minimal) or more during the 3 weeks of placebo adminis-
tration in women with past PMD were 5 women (36%) for
both daytime and nighttime; in control women, the num-
bers were 3 women (20%) for both daytime and nighttime.
One woman with past PMD reported severity scores of 2 or
more during double-blind estradiol administration. There
were no significant differences between women with past
PMD and control women during use of placebo in the num-
ber reporting menstrual bleeding (1 and 2 women, respec-
tively) (Fisher exact test, P values ranged from .20 to >.99).
Finally, the numbers of women reporting vaginal bleeding
did not differ significantly either during the open-label and
double-blind conditions or between the randomized pla-
cebo and estradiol groups (Fisher exact test, P > .99 for all
comparisons). Neither the change in CES-D scores from
open-label estradiol to placebo nor the maximum CES-D
Table 2. Comparisons of Symptom Rating Scores During Open-Label and Double-blind Treatment (continued)
Measure Past PMD Phase
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
Excess worry Yes OL Estradiol 5.4 (3.0) 5.4 (5.0)
.07
Placebo 14.2 (3.0) 14.0 (16.4)
Yes OL Estradiol 7.9 (1.6) 8.4 (7.6)
.55
DB Estradiol 5.0 (1.5) 5.1 (4.4)
No OL Estradiol 3.4 (0.9) 3.5 (3.5)
>.99
Placebo 3.5 (0.9) 3.4 (3.9)
No OL Estradiol 2.7 (0.4) 2.7 (1.6)
>.99
DB Estradiol 2.7 (0.4) 2.8 (1.8)
Decreased
concentration
Yes OL Estradiol 9.1 (3.6) 9.1 (8.2)
.18
Placebo 17.9 (3.6) 17.9 (17.6)
Yes OL Estradiol 9.5 (2.5) 9.9 (11.9)
.82
DB Estradiol 7.6 (2.5) 7.6 (6.4)
No OL Estradiol 3.5 (0.8) 3.5 (3.4)
.82
Placebo 2.9 (0.8) 2.8 (2.4)
No OL Estradiol 2.7 (0.3) 2.6 (1.6)
.82
DB Estradiol 2.3 (0.3) 2.3 (1.1)
Nighttime hot flushes Yes OL Estradiol 1.2 (0.1) 1.1 (0.3)
.43
Placebo 1.5 (0.1) 1.4 (0.5)
Yes OL Estradiol 1.4 (0.2) 1.4 (0.8)
.51
DB Estradiol 1.3 (0.2) 1.1 (0.3)
No OL Estradiol 1.1 (0.1) 1.1 (0.2)
.43
Placebo 1.2 (0.1) 1.2 (0.3)
No OL Estradiol 1.1 (0.1) 1.1 (0.3)
.20
DB Estradiol 1.1 (0.1) 1.0 (0.1)
Daytime hot flushes Yes OL Estradiol 1.2 (0.1) 1.2 (0.3)
.26
Placebo 1.5 (0.1) 1.5 (0.5)
Yes OL Estradiol 1.2 (0.1) 1.2 (0.3)
>.99
DB Estradiol 1.1 (0.1) 1.1 (0.3)
No OL Estradiol 1.2 (0.1) 1.2 (0.2)
>.99
Placebo 1.2 (0.1) 1.2 (0.3)
No OL Estradiol 1.1 (0.03) 1.1 (0.2)
.38
DB Estradiol 1.0 (0.03) 1.0 (0.1)
Abbreviations: BDI, Beck Depression
Inventory; CES-D, Center for
Epidemiologic Studies–Depression
Scale; DB, double-blind;
HDRS, Hamilton Depression Rating
Scale; OL, open-label;
PMD, perimenopausal depression.
aLeast squares means were adjusted
by PROC MIXED (SAS Institute Inc)
using residual maximum likelihood
methods, whereas arithmetic means
are not adjusted.
b P values represent post hoc
Bonferroni comparisons of least
squares means.
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score during placebo use correlated with the absolute
change (ie, difference between open-label estradiol and pla-
cebo) in the plasma levels of either estradiol or FSH.
Discussion
During perimenopause, the incidence of depression
increases and predicts increased all-cause and cardiovascu-
lar mortality.29 The possible role of ovarian steroids in the
onset of PMD is only indirectly suggested by the temporal
coincidence of changes in reproductive function and mood
symptoms as well as by reports13-15 of the short-term efficacy
of estradiol in this condition. In the present study, we
attempted to determine whether sudden, blinded with-
drawal of estradiol would precipitate depressive symptoms
and whether the withdrawal would do so differentially in
women with a history of PMD. Our findings support both
predictions. Estradiol withdrawal precipitated depressive
symptoms in women with a history of PMD (although the
mean depressive symptom scores remained within the nor-
mal ranges), but no depressive symptoms were seen after
estradiol withdrawal in women with no history of PMD. Fur-
thermore, depressive symptoms did not emerge in women
with past PMD who continued to receive estradiol. The
recurrence of depressive symptoms in women with past
PMD occurred in the absence of differences in several mea-
sures that could influence mood including baseline clinical
characteristics (other than PMD), the severity of daytime/
nighttime hot flushes, and plasma hormone levels after
estradiol withdrawal. The lack of depressive symptoms in
the control women despite identical hormone manipulation
(and similar levels of hot flushes and plasma estradiol levels)
demonstrates that estradiol withdrawal differentially affects
central nervous system function in some women so as to
render them susceptible to depression. This finding suggests
that perimenopausal changes in estradiol levels can trigger
depression, but only in the susceptible subgroup.
Our experiment failed to model distinct elements of the
natural course of menopause, including the marked variabil-
ity and higher peak levels of estradiol secretion.30,31 Nonethe-
less, our study demonstrated the ability of withdrawal of es-
tradiol, even from relatively lower levels (ie, relative to the high
plasma levels reported30-33 in some perimenopausal wom-
en), to precipitate depressive symptoms in women with a his-
tory of PMD. Previous clinic-based studies34,35 found no ben-
eficial effects of differing rates of tapering of HT on the
emergence of withdrawal symptoms, suggesting that the rate
of estradiol withdrawal would not influence the onset of es-
tradiol withdrawal-induced symptoms.
In addition to not fully recapitulating estradiol levels in
perimenopause, this study had several limitations. First, the
relatively short duration of estradiol withdrawal could have
reduced the likelihood of precipitating and detecting dis-
tressing hot flushes and, possibly, mood disturbances.
However, both epidemiologic and clinic-based studies15,36,37
suggest that vasomotor symptoms are not uniform accom-
paniments of depression in perimenopause. Moreover, the
duration of withdrawal was sufficient to produce depressive
symptoms (but not hot flushes) in women with past PMD.
Second, blinding could have been compromised by the
onset of vaginal bleeding; however, this occurred infre-
quently and was as commonly reported during estradiol use
(both open-label and double-blind) as it was during estra-
diol withdrawal and occurred in both women with past PMD
and control women. Third, since most of the women in our
sample experienced depression only in the context of peri-
menopause (and had depression responsive to HT), the
findings do not necessarily represent women with PMD
with a history of depression unrelated to perimenopause.
Nonetheless, a large proportion of women with PMD have
first-onset depression,7,38 and small therapeutic trials13-15
suggest that there are no differences in the treatment
response to estradiol in women with first-onset vs recurrent
depression in perimenopause. However, the role of estradiol
withdrawal in PMD cannot be generalized beyond the pre-
sent sample, that is, to either women who experience
depression independent of the menopause transition or,
obviously, those with depression that does not respond to
HT. Fourth, given the retrospective nature of the diagnosis
used in this study, it is possible that recall bias may have led
some women to falsely conclude that the onset of depres-
sion was linked to the menopausal transition. Fifth, women
with past PMD were more symptomatic than were control
women at baseline, and they remained more symptomatic
compared with control women during the open-label
administration of estradiol. We addressed this potential
problem by including scores during the open-label phase as
a covariate in our analysis. Nevertheless, it is possible that
the increase in baseline ratings may have contributed to the
degree of symptom severity experienced during estradiol



















1 2 3 4 5 6
Women with past PMD
Received estradiol weeks 1-6
Received estradiol weeks 1-3
Received placebo weeks 4-6
Control women
Received estradiol weeks 1-3
Received placebo weeks 4-6
Women with past perimenopausal depression (PMD) randomized to placebo
(but not those randomized to estradiol and control women randomized to
either estradiol or placebo) had significantly increased (ie, more symptomatic)
Center for Epidemiologic Studies–Depression Scale (CES-D) scores compared
with scores during the open-label administration of estradiol. In addition, CES-D
scores in women with PMD during use of placebo were significantly increased
compared with the scores of both control women randomized to placebo and
those with past PMD randomized to estradiol. The dosage of estradiol used
throughout the study was 100 μg/d. Data markers indicate the arithmetic mean;
error bars, SE.
Estradiol Withdrawal and Mood in Women With Past Perimenopausal Depression Original Investigation Research
jamapsychiatry.com (Reprinted) JAMA Psychiatry July 2015 Volume 72, Number 7 721
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
Copyright 2015 American Medical Association. All rights reserved.
Table 3. Comparisons of Symptom Rating Scores During Double-blind Treatment
Measure Group Subgroup
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
CES-D score Placebo Past PMD 8.4 (1.0) 8.8 (4.9)
.0004
Control 1.8 (0.9) 1.1 (1.8)
Estradiol Past PMD 2.4 (0.4) 2.8 (1.5)
.07
Control 1.1 (0.3) 0.8 (1.4)
Past PMD Placebo 9.3 (1.0) 8.8 (4.9)
.0004
Estradiol 2.6 (1.1) 2.8 (1.5)
Control Placebo 1.3 (0.3) 1.1 (1.8)
.73
Estradiol 0.6 (0.3) 0.8 (1.4)
HDRS score Placebo Past PMD 5.6 (0.6) 6.6 (4.5)
.0008
Control 2.0 (0.5) 0.9 (0.9)
Estradiol Past PMD 2.2 (0.7) 3.1 (2.6)
>.99
Control 1.3 (0.6) 0.7 (1.1)
Past PMD Placebo 7.1 (0.8) 6.6 (4.5)
.002
Estradiol 2.7 (0.8) 3.1 (2.6)
Control Placebo 0.8 (0.2) 0.9 (0.9)
>.99
Estradiol 0.7 (0.2) 0.7 (1.1)
BDI scale score Placebo Past PMD 3.8 (0.7) 4.3 (3.7)
.02
Control 0.6 (0.7) 0.2 (0.4)
Estradiol Past PMD 0.8 (0.2) 1.1 (1.5)
.68
Control 0.3 (0.2) 0.04 (0.2)
Past PMD Placebo 4.3 (0.7) 4.3 (3.7)
.03
Estradiol 1.1 (0.8) 1.1 (1.5)
Control Placebo 0.2 (0.1) 0.2 (0.4)
>.99
Estradiol 0.05 (0.1) 0.04 (0.2)
Visual analog scale
Depression Placebo Past PMD 12.7 (1.7) 14.0 (10.2)
.004
Control 3.7 (1.7) 2.5 (1.8)
Estradiol Past PMD 5.9 (1.6) 6.8 (7.4)
.82
Control 2.9 (1.4) 2.4 (1.1)
Past PMD Placebo 14.0 (2.2) 14.0 (10.2)
.11
Estradiol 6.6 (2.4) 6.8 (7.4)
Control Placebo 2.6 (0.3) 2.5 (1.8)
>.99
Estradiol 2.3 (0.3) 2.4 (1.1)
Anxiety Placebo Past PMD 15.3 (2.4) 18.2 (17.6)
.04
Control 5.7 (2.3) 2.9 (2.3)
Estradiol Past PMD 8.4 (2.8) 9.6 (9.0)
>.99
Control 6.5 (2.5) 5.3 (8.4)
Past PMD Placebo 19.3 (3.0) 18.2 (17.6)
.08
Estradiol 8.2 (3.3) 9.6 (9.0)
Control Placebo 2.9 (1.6) 2.9 (2.3)
>.99
Estradiol 5.6 (1.7) 5.3 (8.4)
Irritability Placebo Past PMD 18.1 (3.2) 20.4 (17.5)
.03
Control 5.0 (3.1) 2.8 (2.3)
Estradiol Past PMD 5.7 (1.0) 7.7 (7.1)
.67
Control 3.7 (0.9) 2.3 (1.1)
Past PMD Placebo 20.6 (3.2) 20.4 (17.5)
.03
Estradiol 7.1 (3.5) 7.7 (7.1)
Control Placebo 3.0 (0.4) 2.8 (2.3)
.37
Estradiol 2.1 (0.4) 2.3 (1.1)
(continued)
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Table 3. Comparisons of Symptom Rating Scores During Double-blind Treatment (continued)
Measure Group Subgroup
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
Avoid socializing Placebo Past PMD 10.3 (1.5) 12.4 (10.5)
.04
Control 4.3 (1.5) 2.4 (1.8)
Estradiol Past PMD 4.5 (0.7) 4.9 (3.7)
.41
Control 2.8 (0.6) 2.5 (1.0)
Past PMD Placebo 12.5 (1.9) 12.4 (10.5)
.03
Estradiol 4.4 (2.1) 4.9 (3.7)
Control Placebo 2.5 (0.2) 2.4 (1.8)
>.99
Estradiol 2.4 (0.2) 2.5 (1.0)
Early morning
wakening
Placebo Past PMD 12.8 (1.7) 15.8 (14.4)
.03
Control 5.9 (1.6) 3.3 (3.2)
Estradiol Past PMD 7.6 (1.8) 13.5 (9.5)
>.99
Control 8.2 (1.5) 3.3 (3.6)
Past PMD Placebo 17.9 (1.9) 15.8 (14.4)
.06
Estradiol 10.3 (2.2) 13.5 (9.5)
Control Placebo 3.1 (0.7) 3.3 (3.2)
>.99
Estradiol 3.7 (0.7) 3.3 (3.6)
Anhedonia Placebo Past PMD 10.7 (1.9) 12.4 (11.3)
.07
Control 3.8 (1.9) 2.3 (1.7)
Estradiol Past PMD 4.8 (0.8) 5.2 (3.7)
.25
Control 2.5 (0.7) 2.4 (1.0)
Past PMD Placebo 12.6 (2.2) 12.4 (11.3)
.08
Estradiol 4.6 (2.4) 5.2 (3.7)
Control Placebo 2.4 (0.2) 2.3 (1.7)
>.99
Estradiol 2.2 (0.2) 2.4 (1.0)
Decreased energy Placebo Past PMD 16.9 (2.7) 18.9 (14.0)
.02
Control 4.8 (2.6) 2.9 (2.0)
Estradiol Past PMD 7.6 (1.4) 9.6 (7.8)
.35
Control 4.1 (1.2) 3.0 (2.0)
Past PMD Placebo 19.0 (2.9) 18.9 (14.0)
.10
Estradiol 8.9 (3.1) 9.6 (7.8)
Control Placebo 2.9 (0.3) 2.9 (2.0)
>.99
Estradiol 2.9 (0.3) 3.0 (2.0)
Disturbed sleep Placebo Past PMD 19.7 (2.9) 22.7 (17.7)
.02
Control 7.2 (2.8) 4.2 (5.1)
Estradiol Past PMD 9.3 (2.4) 15.6 (13.2)
>.99
Control 9.0 (2.1) 3.8 (4.2)
Past PMD Placebo 25.4 (3.4) 22.7 (17.7)
.07
Estradiol 12.3 (3.7) 15.6 (13.2)
Control Placebo 3.9 (0.8) 4.2 (5.1)
>.99
Estradiol 4.4 (0.8) 3.8 (4.2)
Unmotivated Placebo Past PMD 14.1 (2.1) 14.8 (12.8)
.01
Control 3.8 (2.0) 3.1 (2.8)
Estradiol Past PMD 4.6 (0.8) 7.0 (7.4)
>.99
Control 4.0 (0.7) 2.6 (1.1)
Past PMD Placebo 14.1 (2.2) 14.0 (12.8)
.15
Estradiol 7.2 (2.3) 7.0 (7.4)
Control Placebo 2.9 (0.4) 3.1 (2.8)
>.99
Estradiol 2.8 (0.5) 2.6 (1.1)
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withdrawal but cannot account for the significant differ-
ences that we observed. Finally, it is possible that as yet
unknown factors, the effects of which we could not control,
could contribute to the differential response to estradiol
withdrawal in women with PMD.
There are several mechanisms by which changes in
estradiol levels might mediate the observed effects on
mood. First, estradiol modulates the activity of virtually
every system implicated in the pathogenesis of depression
including regulation of neurotransmitter synthesis and
metabolism, stress axis activation, neuroplasticity (includ-
ing regulation of brain-derived neurotrophic factor), epigen-
esis, and immune system activation.39 Second, estradiol sig-
naling through estrogen receptor β reverses depressive- and
anxiety-like behaviors in animal studies.40-42 Third, reward
responsiveness, which is disturbed in depression,43 is
modulated by estradiol in both rodents and humans.44,45
Finally, discontinuation of long-term estradiol therapy in
postmenopausal women is accompanied by decreases in
medial frontal and temporo-occipital metabolism.46 Thus,
through local signaling or network-level dysfunction, par-
ticularly in frontolimbic regions, estradiol withdrawal could
precipitate affective dysregulation.
What remains unclear is the reason for differential sus-
ceptibility to the mood-destabilizing effects of estradiol
withdrawal. Of interest in this regard is the recent identifi-
cation of increased sensitivity to estrogen regulation among
transcripts that were differentially expressed in women who
developed postpartum depression.47 Alternatively, basic
science studies48 have reported the de novo production of
estradiol from androgens in brain regions involved in mood
regulation (eg, hippocampus). Thus, it is possible that
women who did not develop depressive symptoms after
estradiol withdrawal have sufficient central nervous system
aromatase activity to prevent the development of depres-
sive symptom during declining estradiol secretion.
Table 3. Comparisons of Symptom Rating Scores During Double-blind Treatment (continued)
Measure Group Subgroup
Meana
P ValuebLeast Squares (SE) Arithmetic (SD)
Excessive worry Placebo Past PMD 12.6 (2.3) 14.0 (16.4)
.09
Control 4.9 (2.2) 3.4 (3.9)
Estradiol Past PMD 5.1 (1.1) 5.1 (4.4)
.51
Control 2.7 (0.9) 2.8 (1.8)
Past PMD Placebo 14.9 (2.9) 14.1 (16.4)
.07
Estradiol 3.8 (3.2) 5.1 (4.4)
Control Placebo 3.2 (0.5) 3.4 (3.9)
>.99
Estradiol 3.1 (0.6) 2.8 (1.8)
Decreased
concentration
Placebo Past PMD 15.2 (3.0) 17.9 (17.6)
.12
Control 5.2 (2.9) 2.8 (2.4)
Estradiol Past PMD 6.2 (1.2) 7.6 (6.4)
.33
Control 3.1 (1.1) 2.3 (1.1)
Past PMD Placebo 17.8 (3.3) 17.9 (17.6)
.14
Estradiol 7.0 (3.6) 7.6 (6.4)
Control Placebo 2.6 (0.4) 2.8 (2.4)
>.99
Estradiol 2.5 (0.4) 2.3 (1.1)
Nighttime hot flushes Placebo Past PMD 1.5 (0.1) 1.4 (0.5)
.82
Control 1.2 (0.1) 1.2 (0.3)
Estradiol Past PMD 1.1 (0.1) 1.1 (0.3)
>.99
Control 1.0 (0.1) 1.0 (0.1)
Past PMD Placebo 1.5 (0.1) 1.4 (0.5)
.51
Estradiol 1.1 (0.1) 1.1 (0.3)
Control Placebo 1.2 (0.1) 1.2 (0.3)
.21
Estradiol 1.0 (0.1) 1.0 (0.1)
Daytime hot flushes Placebo Past PMD 1.5 (0.1) 1.5 (0.5)
.23
Control 1.2 (0.1) 1.2 (0.3)
Estradiol Past PMD 1.1 (0.1) 1.1 (0.3)
>.99
Control 1.0 (0.05) 1.0 (0.1)
Past PMD Placebo 1.5 (0.1) 1.5 (0.5)
.18
Estradiol 1.1 (0.1) 1.1 (0.3)
Control Placebo 1.2 (0.04) 1.2 (0.3)
.27
Estradiol 1.0 (0.04) 1.0 (0.1)
Abbreviations: BDI, Beck Depression
Inventory; CES-D, Center for
Epidemiologic Studies–Depression
scale; DB, double-blind;
HDRS, Hamilton Depression Rating
Scale; PMD, perimenopausal
depression.
a Least squares means were adjusted
for symptom rating scores during
open-label estradiol administration,
whereas arithmetic means were not
adjusted.
b P values represent post hoc
Bonferroni comparisons of least
squares means.
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Conclusions
Although women with past PMD had a recurrence of depres-
sive symptoms during estradiol withdrawal, control women
had no perturbations of mood during the same hormonal
manipulation. These observations, in the context of similar
plasma reproductive hormone levels, suggest that normal
changes in ovarian estradiol secretion can trigger an abnor-
mal behavioral state in susceptible women.
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Control 38.1 (2.7) 44.8 (16.9)
Past PMD Placebo 75.7 (3.9) 73.7 (25.9) .0004
Estradiol 28.5 (4.3) 31.8 (29.5)
Control Placebo 94.1 (3.3) 91.3 (26.4) .0004




SI conversion factor: To convert
estradiol and estrone to picomoles
per liter, multiply by 3.671 and 3.699,
respectively.
a Blood samples were centrifuged,
aliquoted, and stored at −70°C until
the time of assay. Blood samples
were assayed for estradiol and
estrone by liquid chromatography-
tandem mass spectrometry
techniques at NMS Laboratories.
Plasma FSH levels were determined
at the National Institutes of Health




bLeast squares means were adjusted
for individual plasma hormone levels
during open-label estradiol
administration (baseline), whereas
arithmetic means are not adjusted.
c P values represent post hoc
Bonferroni comparisons of least
squares means.
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